Bendazac
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[(1-benzyl-1H-indazol-3-yl)oxy]acetic acid | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical |
| Identifiers | |
| CAS Number | 20187-55-7 |
| ATC code | M02AA11 (WHO) S01BC07 (WHO) |
| PubChem | CID 2313 |
| ChemSpider |
2223  |
| UNII |
G4AG71204O |
| KEGG |
D01594 |
| ChEBI | CHEBI:31257 |
| ChEMBL |
CHEMBL1089221 |
| Chemical data | |
| Formula | C16H14N2O3 |
| Molar mass | 282.294 g/mol |
| |
| |
| (verify) | |
Bendazac (or bendazolic acid) is a non-steroidal anti-inflammatory drug used for joint and muscular pain.
Synthesis
Principle action is inhibition of protein denaturation.
Bendazac synthesis: BE 699226; G. Palazzo, U.S. Patent 3,470,194 (1967, 1969 both to Francesco Angelini).
Use of chloroacetamide in the alkylation step, followed by acid hydrolysis produces bendazac (instead of benzydamine).
See also
References
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Tuesday, April 19, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.